- Home
- / Liminal BioSciences
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Liminal BioSciences financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Total Funding
$71.7 M
Revenue
$416 K
FY, 2022
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CAD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 |
|---|---|---|---|---|---|
| Revenue | 47.4M | 27.4M | 3.3M | 1.6M | 416.0K |
| Cost of goods sold | 32.5M | 9.1M | 943.0K | 1.5M | |
| Gross profit | 48.5M | 18.3M | 2.4M | 127.0K | 416.0K |
| Gross profit margin, % | 66.7% | 71.6% | 8.0% | 100.0% | |
| Operating expense total | 123.2M | 129.7M | 88.0M | 125.0M | 20.3M |
| Depreciation and amortization | 153.8M | 17.4M | 29.3M | 6.1M | 1.1M |
| EBITDA | (74.8M) | (111.4M) | (85.6M) | (124.9M) | (19.9M) |
| EBITDA margin, % | -406.6% | -2582.1% | -7845.3% | -4780.3% | |
| EBIT | (229.5M) | (220.0M) | (114.0M) | 19.4M | (17.2M) |
| EBIT margin, % | -802.9% | -3437.6% | 1216.8% | -4140.6% | |
| Interest income | 307.0K | 451.0K | 73.0K | 16.8M | |
| Interest expense | 22.4M | 14.8M | 9.4M | 8.6M | 1.9M |
| Pre tax profit | (257.9M) | (233.3M) | (122.3M) | 12.3M | 697.0K |
| Income tax expense | (20.0M) | (196.0K) | (201.0K) | 119.0K | (525.0K) |
| Net Income | (237.9M) | (233.1M) | (122.1M) | 12.2M | 1.2M |